Stockreport

Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

Zevra Therapeutics, Inc.  (ZVRA) 
PDF Full commercial launch of OLPRUVA at the end of January 2024, with market access growing to ~75% of covered lives as of May 1, 2024 Arimoclomol NDA review underway with [Read more]